Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCHR1 | Q99705 | 13/20 | 0.54 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 2/20 | 0.35 |
| ▸ | RAB9A | P51151 | 2/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15334556 | 0.89 | MCHR1 (0.56) | MCHR1KCNH2MRGPRX4 | |
| SCHEMBL12040542 | 0.88 | MCHR1 (0.56) | MCHR1KCNH2NPC1RAB9AMRGPRX4 | |
| Hydrochloric Acid SCHEMBL9995187 | 0.87 | MCHR1 (0.55) | MCHR1KCNH2NPC1RAB9AMRGPRX4 | |
| SCHEMBL1724471 | 0.82 | MCHR1 (0.73) | MCHR1 | |
| SCHEMBL12040640 | 0.80 | MCHR1 (0.55) | MCHR1KCNH2MRGPRX4 | |
| SCHEMBL9989229 | 0.80 | MCHR1 (0.54) | MCHR1LMNAMAPTSMN1; SMN2 | |
| SCHEMBL12040595 | 0.80 | MCHR1 (0.62) | MCHR1KCNH2 | |
| SCHEMBL1724058 | 0.80 | MCHR1 (0.62) | MCHR1KCNH2 | |
| SCHEMBL12040553 | 0.80 | MCHR1 (0.54) | MCHR1KCNH2MRGPRX4 | |
| SCHEMBL12040545 | 0.80 | MCHR1 (0.57) | MCHR1KCNH2TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8563583-B2 | Pyridone analogs useful as melanin concentrating hormone receptor-1 antagonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-10-22 | — | — | US | disclosed |
| US-20110319449-A1 | PYRIDONE ANALOGS USEFUL AS MELANIN CONCENTRATING HORMONE RECEPTOR-1 ANTAGONISTS | BRISTOL-MYERS SQUIBB COMPANY | 2011-12-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110319449-A1 | PYRIDONE ANALOGS USEFUL AS MELANIN CONCENTRATING HORMONE RECEPTOR-1 ANTAGONISTS | MCHR1, MCHR2, MC1R | MCHR1 1/4885KCNH2 3550/4885NPC1 2530/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.